Description

Redivek (imatinib) hard capsules 400 mg. №30

Ingredients

Each hard capsule contains 400 mg of imatinib.

Dosage

The recommended dosage of Redivek is determined by a healthcare provider based on individual factors. It is typically taken once daily with a full glass of water.

Indications

Redivek is indicated for the treatment of certain types of leukemia and other cancers. It works by interfering with the growth of cancer cells.

Contraindications

Do not take Redivek if you are allergic to imatinib or any other ingredients in the capsules. It is important to inform your healthcare provider about any medical conditions or medications you are taking before starting Redivek.

Directions

Follow the instructions provided by your healthcare provider for the best results. Do not crush or chew the capsules. Swallow them whole with water.

Scientific Evidence

Imatinib, the active ingredient in Redivek, has been extensively studied for its efficacy in treating various cancers. Research has shown that imatinib inhibits specific enzymes that are critical for the growth and survival of cancer cells. Clinical trials have demonstrated significant improvements in survival rates and quality of life in patients with certain types of leukemia and gastrointestinal stromal tumors (GIST) when treated with imatinib.

Additional Information

It is important to attend regular follow-up appointments with your healthcare provider while taking Redivek to monitor your response to the medication and any potential side effects. If you experience any severe or persistent side effects, contact your healthcare provider immediately.

Imatinib is considered a targeted therapy, meaning it specifically targets cancer cells while minimizing damage to healthy cells. This targeted approach can result in fewer side effects compared to traditional chemotherapy. However, it is essential to discuss the potential risks and benefits of treatment with your healthcare provider.

Overall, Redivek (imatinib) hard capsules 400 mg. №30 offer a promising treatment option for individuals with certain types of leukemia and other cancers. The scientific evidence supporting the efficacy of imatinib, along with its targeted pharmacological action, makes it a valuable addition to cancer treatment regimens.